Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8069-8080
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8069
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8069
Ref. | Treatment regimen | Number of patients, n (%) | Study results |
Zhang et al[37], 2020 | TKI: Lenvatinib. PD-1 antibody: Pembrolizumab/Sintilimab/Toripalimab | 33 | Success rate of conversion (imaging): 42.4%. Actual surgery rate following conversion: 30.3% |
Li et al[40], 2017 | TACE + sorafenib | 142 | Second-stage resection rate following stage reduction: 14.8% |
He et al[39], 2019 | HAIC + sorafenib | 125 | Surgical resection rate following conversion: 12.8% |
He et al[41], 2018 | HAIC + sorafenib | 35 | Surgical resection rate following conversion: 14.3% |
Zhang et al[42], 2021 | HAIC + TKI + PD-1 antibody (1, 7, and 17 patients used sorafenib, apatinib, and lenvatinib, respectively) | 25 | Surgical resection rate following conversion: 56.0%, 7 patients (28.0%) achieved pathologically complete remission |
He et al[38], 2021 | Lenvatinib + toripalimab + HAIC | 71 | Surgical resection rate following conversion: 12.7% |
- Citation: Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080
- URL: https://www.wjgnet.com/1007-9327/full/v27/i47/8069.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8069